Skip to main content
main-content

Spondyloarthropathies

Ankylosing spondylitis

14-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

Bimekizumab may offer a new therapeutic option for patients with ankylosing spondylitis, findings from the BE AGILE study indicate.

22-05-2019 | Psoriatic arthritis | News

Comorbidities linked to worse physical function in psoriatic arthritis patients

Psoriatic arthritis patients with multiple comorbidities have worse physical function than those with just one comorbidity, according to a cross-sectional analysis of the CARMA study of patients from daily clinical practice in Spain.

15-05-2019 | Secukinumab | News

Pooled analysis demonstrates favorable long-term safety profile of secukinumab

Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has a favorable long-term safety profile among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis.

29-04-2019 | Etanercept biosimilar | News

FDA approves etanercept biosimilar

Click through for more information on this announcement

16-04-2019 | Sexual and reproductive health | News

Inflammatory arthritis may impact sexual function

Findings from a systematic review suggest that sexual dysfunction is common among both men and women with inflammatory arthritis, highlighting the importance of including sexual health in the routine management of rheumatic disease.

12-04-2019 | Ankylosing spondylitis | News

Infliximab withdrawal not recommended for AS patients in remission

The decision to discontinue infliximab in ankylosing spondylitis patients who have achieved sustained remission “should be taken with considerable caution,” say Spanish researchers who found that over half relapsed after the tumor necrosis factor inhibitor was withdrawn.

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

25-02-2019 | Vaccination | Highlight | News

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

13-02-2019 | Ankylosing spondylitis | News

VTE risk elevated in patients with ankylosing spondylitis

Patients with ankylosing spondylitis have a significantly increased risk for venous thromboembolism compared with the general population, with the risk apparently highest in the first year after diagnosis, study findings indicate.

30-01-2019 | Axial spondyloarthritis | News

Elevated fecal calprotectin linked to worse disease activity in axSpA

Elevated levels of fecal calprotectin, an indicator of gut inflammation, are associated with increased disease activity and reduced physical function in patients with axial spondyloarthritis, research shows.

29-01-2019 | Secukinumab | News

IBD ‘uncommon’ in patients treated with secukinumab

Inflammatory bowel disease is an “uncommon” occurrence among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis who are treated with the interleukin-17A inhibitor secukinumab, researchers report.

21-01-2019 | Ankylosing spondylitis | News

Trial results back TNF inhibitor dose-reduction strategy in ankylosing spondylitis patients

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

04-12-2018 | Ankylosing spondylitis | News

Elevated CRP levels may point to better secukinumab response in AS patients

Ankylosing spondylitis patients with elevated C-reactive protein levels may experience greater benefits from treatment with the interleukin-17A inhibitor secukinumab than those with lower levels of the inflammatory marker, researchers report.

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

13-11-2018 | Ankylosing spondylitis | Highlight | News

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

03-10-2018 | Ankylosing spondylitis | Article

Influence of HLA-B27 on the ankylosing spondylitis phenotype: Results from the REGISPONSER database

Arévalo M et al. Arthritis Res Ther 2018; 20: 221. doi: 10.1186/s13075-018-1724-7

Further investigation of filgotinib warranted in ankylosing spondylitis patients

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

Image Credits